Mining safety signals of letermovir drug combinations: real-world pharmacovigilance analysis. (PubMed, Transplant Cell Ther) - Oct 4, 2025 - "LMV use may induce cardiac AE signals such as acute heart failure, pericardial effusion, and atrial fibrillation, and may increase the risk of herpes virus reactivation. When LMV is used in combination with drugs such as cyclosporine or tacrolimus, it may exacerbate hepatic and renal toxicity. Acute heart failure and atrial fibrillation AE signals were detected when combined with cyclosporine. Future efforts should focus on the safety of LMV in clinical practice and real-world settings, with optimized medication strategies to minimize risks and enhance therapeutic outcomes."
Adverse events • Journal • Real-world evidence • Acute Graft versus Host Disease • Acute Kidney Injury • Aplastic Anemia • Atrial Fibrillation • Cardiovascular • CNS Disorders • Congestive Heart Failure • Epstein-Barr Virus Infections • Febrile Neutropenia • Gastrointestinal Disorder • Graft versus Host Disease • Heart Failure • Hematological Disorders • Hepatology • Immunology • Liver Failure • Nephrology • Neutropenia • Transplantation
|
|
Chao Meng; Dan Sun; Jingjing Lan; Juan Ren; Mengmeng Teng; Shiqi Cheng; Siying Chen; Xiaoning Wang; Yalin Dong; Yulan Qiu; Ziyuan Ma
|